1. Antiretroviral Drugs

13. New Guidelines-Recommendations Defer; some treat if viral load is >55,000 / mL >350 Asymptomatic Treat; some defer especially if viral loads < 20,000 / mL 200-349 Asymptomatic Treat < 200 Asymptomatic Treat Any Symptomatic Recommendations CD4 / mcL Category

16. Antiretrovirals Non-nucleoside Analogs Nucleoside Analogs SUBCLASS Delavirdine mesylate (DLV) Nevirapine (NVP) Efavirenz (EFV) Didanosine (ddI) Lamivudine (3TC) Stavudine (d4T) Zalcitabine (ddC) Zidovudine (ZDV, AZT) Abacavir (ABC) Tenofivir Disoproxil Fumarate (TDF) AZT / 3TC AZT / 3TC / ABC GENERIC Rescriptor Viramune Sustiva Videx Epivir Zerit Hivid Retrovir Ziagen Viread Combivir Trizivir Reverse Transcriptase Inhibitors TRADE CLASS

17. Antiretrovirals Crixivan Viracept Norvir Invirase Agenerase Reyatz Lexiva Kaletra Indinavir sulfate (IDV) Nelfinavir mesylate (NFV) Ritonavir (RTV) Saquinavir mesylate (SQV) Amprenavir (APV) Atazanavir Fosamprenavir (f-APV) LPV / RTV Protease Inhibitors Enfuvirtide GENERIC Fuzeon, T-20 Fusion Inhibitor TRADE CLASS

21. For IDV, monitor for nephrolithisis, UA for crystalluria, increased urine pH Urinalysis If Sx of lactic acidosis associated with NNRTIs Serum Lactate Q3-4 mo, monitor for NNRTIs If elevated at baseline, monitor within 1-2 mo Lipid Profile Q 3-6 mo, more closely for pancreatitis Amylase / Lipase Frequency / Indication Lab Test Q 3-6 mo, more freq for abnl values & elevated LFTs LFTs Q 3-6 mo, Glucose monitoring Q 3-4 mo Serum Chemistries B12 deficiency m neuropathy vs. HAART Tx induced neuropathy Vitamin B12 Q 3-6 mo, more freq with low values or bone marrow toxicities CBC with DIFF Dx, before Tx, 2-8 wks after start of Tx HIV Viral Load Dx, 3-6 mo, response to Tx CD4

61. Retrovirus: DNA Transcription

62. Retrovirus: Viral RNA Transcription

63. Retrovirus Production

64. Viral Replication